[144] Mineralys Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) filed a Form 144 indicating a proposed insider sale of 59,925 common shares through Merrill Lynch on or about 30 Jul 2025 on the NASDAQ. The shares have an aggregate market value of $884,370 and represent less than 0.1 % of the company’s 65,175,287 shares outstanding.

The securities were obtained via eight vesting events of restricted stock units between 10 Mar 2023 – 10 Oct 2023 under the company’s equity compensation plan. The same account holder sold 24,511 shares in the past three weeks, generating $348,560 in gross proceeds. By signing the notice, the seller affirms lack of undisclosed adverse information regarding MLYS.

Positive

• None.

Negative

• Insider selling: Proposed sale of 59,925 shares ($884k) plus 24,511 shares already sold this month may be viewed negatively by investors due to sentiment concerns.

Insights

Securities Analyst

TL;DR – Insider plans to sell ~$0.9 m in stock after recent ~$0.35 m sales; small relative size but potential sentiment drag.

The Form 144 shows an additional 59,925-share sale request worth $884k, following 24,511 shares already sold this month. While the total is immaterial to the 65 m-share float, clustered insider selling can influence investor perception, particularly for a development-stage biotech that relies on equity financing. No information on motivation or remaining holdings is provided, so impact is limited to sentiment rather than fundamentals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	59925	884370.10	65175287	07/30/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			35684	03/10/2023	Granted as part of issuer equity compensation plan
Common Stock	04/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			3592	04/10/2023	Granted as part of issuer equity compensation plan
Common Stock	05/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			3593	05/10/2023	Granted as part of issuer equity compensation plan
Common Stock	06/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			3592	06/10/2023	Granted as part of issuer equity compensation plan
Common Stock	07/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			3593	07/10/2023	Granted as part of issuer equity compensation plan
Common Stock	08/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			3592	08/10/2023	Granted as part of issuer equity compensation plan
Common Stock	09/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			3593	09/10/2023	Granted as part of issuer equity compensation plan
Common Stock	10/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			2686	10/10/2023	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Adam Levy 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	07/11/2025	10758	155454.18
Adam Levy 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	07/28/2025	12946	181803.62
Adam Levy 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	07/29/2025	807	11301.90

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Mineralys Therapeutics (MLYS) shares are being proposed for sale?

The Form 144 covers 59,925 common shares.

What is the market value of the proposed MLYS share sale?

The aggregate market value disclosed is $884,370.

When is the proposed sale date for the MLYS shares?

The approximate sale date listed is 30 July 2025.

Has the insider sold MLYS shares recently?

Yes. 24,511 shares were sold on 11 Jul, 28 Jul, and 29 Jul 2025, raising $348,560.

What percentage of Mineralys’s outstanding shares does the proposed sale represent?

It represents less than 0.1 % of the 65,175,287 shares outstanding.

How were the shares to be sold originally acquired?

They were acquired through vesting of restricted stock units between March and October 2023.